Huntington’s Disease Clinical Trials

EvergreenHealth Research is part of a large Huntington's disease consortium through the National Institutes of Health.

Huntington Study Group: The Huntington Study Group (HSG) is a non-profit group of physicians and other health care providers from medical centers in the United States, Canada, Europe, Australia, New Zealand and South America, experienced in the care of Huntington patients and dedicated to clinical research of Huntington disease. The HSG was formed in 1993, prompted by the recognition that clinical research in Huntington disease (HD) required the participation of large numbers of research patients (subjects) under the cooperative care of skilled and experienced research physicians.

Adults with Manifest HD

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's Disease

This study will evaluate the efficacy, safety, and biomarker effects of a study drug, RO7234292 (RG6042), compared with placebo in patients with manifest Huntington's disease (HD).

Currently enrolling

Who may be eligible to participate?
Subjects 25 to 65 years of age, inclusive, with manifest HD diagnosis may be eligible. Other inclusion and exclusion criteria may apply.

What does participation involve?
Prospective subjects will undergo screening assessments during a 4-week screening period. Eligible subjects will be randomly assigned to receive RO7234292 every 8 weeks, RO7234292 every 16 weeks, or placebo every 8 weeks by intrathecal injection.

Investigator: Pinky Agarwal, MD, FAAN

For More Information: contact EvergreenHealth Research Services at 425.899.5385 or email

Enroll-HD Identifier: NCT01574053

Enroll-HD: A Prospective Registry Study in a Global Huntington Disease (HD) Cohort.

Enroll-HD is a longitudinal, observational, multinational study that will integrate two existing Huntington's Disease (HD) registries, REGISTRY in Europe and COHORT in North America and Australia, while also expanding to include sites in Latin America and Asia. With no end date and annual assessments, the goal of Enroll-HD is to build a large and rich database of longitudinal clinical information and biospecimens. This database will serve as a basis for future studies aimed at developing tools and biomarkers for progression and prognosis, identifying clinically relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies.

Who may be eligible to participate?

  • Carriers: This group comprises the primary study population and consists of individuals who carry the HD gene expansion mutation.
  • Controls: This group comprises the comparator study population and consists of individuals who do not carry the HD expansion mutation

Investigator: Pinky Agarwal, MD, FAAN

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email

Contact Us

12039 NE 128th Street
Suite 300
Kirkland, WA 98034

Get Directions

425.899.5385  Phone

Office Hours

Mon-Fri   8 a.m. - 5 p.m.

Send Email